Latest News

  • Getting Drugs a Companion Diagnostic Can be a Tricky Proposition

    Diagnostics World | Companion diagnostics (CDx) have revolutionized the treatment of cancer by helping to improve the safety and tolerability of targeted drugs—a key feature of precision medicine. The U.S. Food and Drug Administration (FDA) has to date approved nearly 180 CDx, many for rare diseases but only four of those outside of oncology.

    Aug 7, 2024
  • GE HealthCare, AWS Collaborate on Gen AI Models

    Diagnostics World | GE HealthCare and Amazon Web Services have announced a strategic collaboration to develop purpose-built foundation models and generative artificial intelligence (AI) applications designed to help clinicians improve medical diagnostics and patient care.

    Aug 6, 2024
  • ‘Reimagined’ Community Pharmacists To Do More Point-of-Care Testing

    Diagnostics World | Evidence is mounting that public health in the U.S. could get a big boost by better engaging community pharmacists in providing acute and chronic care services. These are highly trained clinicians in “extremely accessible” locations no more than five miles from the home of 95% of Americans.

    Aug 1, 2024
  • Alzheimer’s Disease Blood Testing Matures

    Diagnostics World | A study published in JAMA yesterday suggests blood tests can more accurately detect Alzheimer’s disease than physicians, and points to a way forward for more extensive Alzheimer’s testing. More blood testing developments are on display at this week's Alzheimer’s Association International Conference.

    Jul 29, 2024
  • Boehringer Ingelheim Teams Up With Brainomix, New Diagnostic For Multiple Sclerosis, More

    Diagnostics World | Researchers at The Australian National University (ANU) have developed a deep learning algorithm, known as DEPLOY, to classify central nervous system tumors into 10 major categories from histopathology images. The goal is to optimize treatment with a faster, more accessible diagnostic approach than the state-of-the-art practice of DNA methylation-based profiling, which can take weeks.

    Jul 25, 2024
  • Element Biosciences Commercializing Platform, NOWDiagnostics At-Home Tests, More

    Diagnostics World | Element Biosciences nets $277 million to launch combined sequencing and cyto-profiling platform; NOWDiagnostics raises $22.5 million for at-home diagnostic tests; and more.

    Jul 24, 2024